Ocular Therapeutix (OCUL) Assets Average (2014 - 2026)

Ocular Therapeutix's Assets Average history runs 13 years deep, the most recent figure standing at $770.3 million for Q1 2026.

• On a quarterly basis, Assets Average rose 78.34% year-over-year to $770.3 million in Q1 2026; TTM through Mar 2026 was $770.3 million, a 78.34% increase from a year earlier, with the FY2025 full-year figure at $633.0 million, up 78.31% from the prior year.
• Assets Average rose to $770.3 million in Q1 2026 per OCUL's latest filing, from $609.5 million in the prior quarter.
• Across five years, Assets Average topped out at $770.3 million in Q1 2026 and bottomed at $125.6 million in Q2 2023.
• The 5-year median for Assets Average is $395.5 million (2024), against an average of $346.1 million.
• Across the five-year window, Assets Average slumped 30.38% in 2023 and jumped 320.51% in 2024, its largest moves.
• Year by year, Assets Average stood at $153.9 million in 2022, then surged by 34.62% to $207.2 million in 2023, then surged by 128.81% to $474.2 million in 2024, then grew by 28.54% to $609.5 million in 2025, then gained by 26.39% to $770.3 million in 2026.
• Per Business Quant, the three latest OCUL Assets Average figures stand at $770.3 million (Q1 2026), $609.5 million (Q4 2025), and $431.1 million (Q3 2025).